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Busulfan, cyclophosphamide, and etoposide (BuCyE) is a commonly used conditioning regimen for autologous
stem cell transplantation (ASCT). This multicenter, phase II study examined the safety and efﬁcacy of BuCyE
with individually adjusted busulfan based on preconditioning pharmacokinetics. The study initially enrolled
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended
due to high early treatment-related mortality (TRM) in patients > 65 years. BuCyE outcomes were compared
with contemporaneous recipients of carmustine, etoposide, cytarabine, and melphalan (BEAM) from the
Center for International Blood and Marrow Transplant Research. Two hundred seven subjects with HL
(n ¼ 66) or NHL (n ¼ 141) were enrolled from 32 centers in North America, and 203 underwent ASCT. Day 100
TRM for all subjects (n ¼ 203), patients > 65 years (n ¼ 17), and patients  65 years (n ¼ 186) were 4.5%,
23.5%, and 2.7%, respectively. The estimated rates of 2-year progression-free survival (PFS) were 33% for HL
and 58%, 77%, and 43% for diffuse large B cell lymphoma (DLBCL; n ¼ 63), mantle cell lymphoma (MCL;
n ¼ 29), and follicular lymphoma (FL; n ¼ 23), respectively. The estimated rates of 2-year overall survival (OS)
were 76% for HL and 65%, 89%, and 89% for DLBCL, MCL, and FL, respectively. In the matched analysis rates of
2-year TRM were 3.3% for BuCyE and 3.9% for BEAM, and there were no differences in outcomes for NHL.
Patients with HL had lower rates of 2-year PFS with BuCyE, 33% (95% CI, 21% to 46%), than with BEAM, 59%
(95% CI, 52% to 66%), with no differences in TRM or OS. BuCyE provided adequate disease control and safety in
B cell NHL patients  65 years but produced worse PFS in HL patients when compared with BEAM.
 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).INTRODUCTION II trial was designed to examine conditioning with a
Hodgkin (HL) and non-Hodgkin lymphoma (NHL)
constitute a biologically heterogeneous group of commonly
occurring hematologic malignancies with marked variability
in clinical behavior, treatment approaches, and response to
conventional therapy. Autologous hematopoietic stem cell
transplantation (ASCT) is a useful therapeutic modality for
many patients with relapsed HL and relapsed or high-risk
NHL. Patients with relapsed/refractory HL who received
high-dose therapy (HDT) and ASCT as compared with con-
ventional salvage chemotherapy also experienced improved
outcomes [1-4]. Prospective randomized trials and several
retrospective studies have demonstrated improved out-
comes when ASCT is used for consolidation after salvage
chemotherapy in patients with relapsed aggressive NHL
[5-10]. A randomized trial also showed that ASCT beneﬁted
patients with relapsed follicular lymphoma (FL) [11], which
was further supported by registry data [12]. HDT and ASCT as
initial therapy for patients with mantle cell lymphoma (MCL)
and diffuse large B cell lymphoma (DLBCL) with high-risk
International Prognostic Index scores remains controversial
but has been commonly used [13-18]. At present, however,
only limited data suggest any speciﬁc HDT regimen offers
beneﬁts over alternatives [19-24].
Busulfan (Bu), an alkylating agent, has been shown to be
an effective component of the conditioning regimen for
myeloablative autologous and allogeneic SCT [1,4,7,25-29].
One of the theoretical advantages of Bu-based HDT regimens
over alternatives is that methods for monitoring plasma
concentrations have been well established and individual-
ized dosing is therefore possible [30]. Pharmacokinetics
(PK)-directed dose adjustment for Bu was originally devel-
oped to avoid unpredictable overexposure and resultant
unfavorable adverse effects such as vomiting and veno-
occlusive disease of the liver (sinusoid obstruction
syndrome), especially when Bu was available only in an oral
formulation [25,27,30]. The introduction of i.v. Bu bypasses
the problem of variable drug absorption from the gastroin-
testinal tract, which has reduced the incidence of adverse
events (AEs). Moreover, single-institution studies showed
improvement in overall survival (OS) for patients with NHL
when oral Bu was replaced by i.v. Bu in HDT conditioning for
ASCT [25,27,31], but multicenter data are lacking. This phasePK-directed dosing regimen for i.v. Bu combined with
cyclophosphamide and etoposide (BuCyE) in a multicenter
setting and to compare this approach with conditioning with
carmustine, etoposide, cytarabine, and melphalan (BEAM)
using data collected from the Center for International Blood
and Marrow Transplant Research (CIBMTR).METHODS
Study Design
This prospective, multicenter, single-arm, phase II study investigated
the safety and efﬁcacy of an i.v. BuCyE regimen with PK-directed Bu dosing.
The primary objective was to evaluate the clinical outcomes including
progression-free survival (PFS; primary endpoint), OS, transplant-related
mortality (TRM), and overall response rate. TRM was deﬁned as a death
after transplant due to any cause other than disease progression. Toxicity
was deﬁned by the National Cancer Institute Common Terminology Criteria
for Adverse Events, version 3. The secondary objective was to compare the
clinical outcomes of subjects receiving the BuCyE regimen with those
receiving a conditioning regimen with BEAM from centers not participating
in this clinical trial, as obtained from CIBMTR registry data [5,6,12,32].
CIBMTR data management procedures have been described previously [33].
In addition, the accuracy of PK-directed BU dose adjustment using the
test-dose method was evaluated.Study Eligibility
Eligible subjects were those who required a ﬁrst ASCT for HL and B cell
NHL. All subjects had relapsed disease after initial therapy or were initially
refractory to an anthracycline-based chemotherapy and had achieved
complete remission (CR) or partial remission (PR) after salvage chemo-
therapy according to the Cheson criteria [34]. Additionally, subjects with
NHL with International Prognostic Index score of 4 to 5 [35] or MCL were
eligible for study treatment as a part of primary therapy. All subjects were
required to have had an Eastern Cooperative Oncology Group performance
status of 0 to 2, with at least 2  106 CD34þ cells/kg previously stored.
Patients with major organ dysfunction or prior treatment with Bu or gem-
tuzumab ozogamicin were excluded.
The study initially enrolled subjects ages 18 to 80 years, but the protocol
was amended to reduce the upper age limit to 65 years because of a high
TRM rate at 100 days post-transplant for subjects aged > 65 years. All
subjects provided written informed consent in accordance with the Decla-
ration of Helsinki principles to participate in this study. The trial was
registered at www.clinicaltrials.gov as NCT00948090.
The same eligibility criteria were applied to the comparator group.
Selected patients were ages 18 to 65 years who had received ASCT with
BEAM conditioning from 2008 to 2010 in US and Canadian transplant cen-
ters not participating in the above-mentioned clinical trial and who were
registered with CIBMTR.
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The method of adjusting Bu dose per patient via individual PK param-
eters has been reported previously [36]. In brief, 6 serial blood samples were
collected in sodium heparin tubes after administration of the i.v. Bu test dose
(initial therapeutic drug monitoring [TDM]) and the ﬁrst individualized
conditioning dose on day 8 (conﬁrmatory TDM). For the initial TDM a test
dose of i.v. BU (.8 mg/kg) was administered over 2 hours between days 14
and11. This dose was intended to achieve an area under the curve (AUC) of
1000 to 1500 mM$min. Blood samples were collected at the end of the
2-hour infusion and at 15, 30, 120, 180, and 240 minutes thereafter. For the
conﬁrmatory TDM on day 8, individual i.v. Bu doses were calculated to
achieve a total AUC of 20,000 mM$min, including the AUC from the test and
conﬁrmatory doses [4,30]. Samples for conﬁrmatory TDM were collected at
the end of the 3-hour infusion and at 30, 90,180, and 300minutes thereafter.
The ﬁrst sample for both the test dose and conﬁrmatory TDM were
drawn at the end of the infusion, and no samples were drawn during the
infusion. Samples were stored on wet-ice or refrigerated immediately after
collection, centrifuged at 4C, and stored at 20C or below until shipping.
To allow same-day sample shipping and expedite availability of PK results,
test dose and conﬁrmatory TDM sampling were limited to 240 and
300 minutes after the end of infusion, respectively. Standard sampling time
points were used for the test dose, based on a sampling schedule of .8 mg/kg
every 6 hours [37-39]. For the conﬁrmatory TDM sampling, Bu clearance and
AUC estimates have been shown to be comparable from PK sampling over 8
(300 minutes after the end of infusion), 11, and 24 hours after the start of
infusion for every 24-hour administration, and thus sampling was limited to
300 minutes after the end of infusion [40].
The PK laboratory at the Seattle Cancer Care Alliance measured plasma
Bu concentrations and recommended individualized Bu dosing. Concen-
trations were analyzed by gas chromatography with mass selective detec-
tion as previously described [41]. The dynamic range was from 62 to
4500 ng/mL and the intraday and interday coefﬁcient of variations were less
than 5% and 8%, respectively. Bu AUC from time 0 to inﬁnity and its esti-
mated corresponding clearance were determined using a 1-compartment
ﬁrst-order elimination model via WinNonlin version 5.2 (Pharsight, Sun-
nyvale, CA) [38,40].
Targeted daily AUC during the conditioning regimen was calculated as
targeted daily conditioning AUC (mM$min) ¼ [20,000 (mM$min)  test dose
measured AUC (mM$min)]/4. The conditioning regimen daily Bu dose was
then calculated as Bu i.v. daily conditioning dose (mg) ¼ test dose
(mg)  targeted daily conditioning AUC (mM$min)/test dose measured AUC
(mM$min). Accuracy of the test dose prediction was assessed by the percent
error calculation: [(predicted AUCday-8 by the test dose  conﬁrmed AUCday-
8)/conﬁrmed AUCday-8] 100. Accuracy of the dose adjustment was assessed
by the percent error calculation: [(conﬁrmed AUCday-8  target AUCday-8)/
target AUCday-8]  100.
Conditioning Regimen with BuCyE
The conditioning regimen consisted of PK-directed doses of Bu on
days 8 through 5 (see previous section), etoposide 1.4 g/m2 on day 4,
and cyclophosphamide 2.5 g/m2 on days 3 and 2, followed by stem cell
infusion on day 0. Individualized doses of i.v. Bu were administered over
3 hours once daily. Intravenous Bu doses on days 6 and 5 were modiﬁed
only when the second PK results on day 8 indicated further adjustment
were required to achieve Bu exposure of 20,000 mM$min (20%; cumulative
Bu exposure between 16,000 and 24,000 mM$min). Although no seizure
prophylaxis was instituted during the test dose of i.v. Bu administration,
benzodiazepines and/or levetiracetamwere used as antiseizure medications
for conditioning. Peritransplant palifermin and post-transplant use of
colony-stimulating factor use were not restricted.
Statistical Analysis
The endpoints of PFS and OS were depicted graphically by Kaplan-Meier
curves. Median survival in months, with 95% conﬁdence intervals (CIs), and
1- and 2-year survival rates were also estimated. Disease responses were
summarized by frequency and percentage at each of the speciﬁed time
points. Efﬁcacy analyses were based on the modiﬁed intention-to-treat data
set.
This study had a prespeciﬁed endpoint (as described in the approved
clinical protocol) comparing efﬁcacy of BuCyE with BEAM from CIBMTR
registry data. Baseline characteristics of patients enrolled in this clinical trial
65 years of age or younger were used to match with CIBMTR control sub-
jects. All patients from the phase II study selected for efﬁcacy analyses were
matched with up to 4 patients treated with BEAM obtained from CIBMTR to
provide approximately 80% power to demonstrate 11% difference in the
2-year PFS rate, assuming that the 2-year PFS rates for BuCyE and BEAM
were 66% and 55%, respectively [24,42]. The 4 criteria used for matching
were age  10 years, Karnofsky Performance Score (90%, <90%), diseasestatus before transplant as deﬁned above (CR1, CR2 or higher, PR), and
histology (HL, FL, DLBCL, MCL, Burkitt, and others). All patients were
followed-up for at least 1 year until May 2013, which provided an approx-
imatemedian 2-year follow-up for this study. Follow-up visits were timed to
match the CIBMTR registry follow-up time points for data comparability:
day 100, 6 months, 1 year, and every year after 1 year.
Baseline characteristics at transplantationwere tabulated and compared
for the phase II BuCyE group and the matched CIBMTR cohort conditioned
with BEAM. Outcomes were tabulated for patients in the phase II BuCyE trial
and compared with the matched BEAM patients from the CIBMTR. Survival
curves were constructed using the Kaplan-Meier method and were
compared by a 2-sided log-rank test. Multivariable Cox regression analyses
were conducted to compare clinical outcomes after HCT between BuCyE and
BEAM. To account for the intracluster correlation resulting from covariates
matching, a marginal models approach was used in all comparisons. Mar-
ginal Cox models [43] were used to evaluate prognostic factors for PFS, TRM,
and OS. The proportional hazards assumption was met. An interaction test
indicated a differential effect of conditioning regimen bydisease type on PFS;
therefore, the comparisons are presented by disease type. A level of signif-
icance (a) of .05 was deﬁned as statistically signiﬁcant. All statistics were
computed using SAS version 9.3 (SAS Statistical Institute, Cary, NC, USA).RESULTS
Patient Disposition and Demographics
Two hundred seven subjects with HL (n ¼ 66) or NHL
(n ¼ 141) were enrolled from 32 centers in the United States
and Canada between February 2010 and April 2012. Four
subjects did not proceed with ASCT because of insurance or
eligibility issues. One patient who experienced a syncopal
episode after etoposide administration was not treated with
cyclophosphamide and discontinued from the study on
day 1. This patient was included in the intent-to-treat
population, because stem cells were infused as planned. In
addition, 4 patients were identiﬁed as ineligible but were
included in the intent-to-treat analyses. These patients were
deemed ineligible due to T cell lymphoma (n ¼ 1), failure to
conﬁrm CR or PR (n ¼ 1), history of hepatitis C (n ¼ 1), and 1
patient with FL who did not receive prior anthracycline. The
study initially enrolled subjects ages 18 to 80, but the pro-
tocol was amended to reduce the upper age limit to 65 years
due to a high TRM rate at 100 days post-transplant for sub-
jects > 65 years. We report safety for all subjects undergoing
ASCT (n ¼ 203) and efﬁcacy from those aged  65 years
(n¼ 186) and recipients of BuCyEwhowerematched to up to
amaximum of 4 BEAMpatients yielding a total of 729 control
subjects.
At baseline, 67% of subjects were men, 87% were white
and 6% were African American, and 96% had an Eastern
Cooperative Oncology Group performance status of 0 to 1
(Table 1). Median time from initial diagnosis to the autolo-
gous transplant was 18.4 months (range, 71 days to
262 months). Lymphoma subtypes and disease status at
transplantation are described in Table 1.PK-Directed Dose Adjustment of Bu
Of the 203 subjects undergoing ASCT in the present study,
200 subjects used individualized Bu doses determined by
initial TDM, whereas 3 subjects used 3.2 mg/kg on days 8
and 7 due to nonassessable test PK results. Conﬁrmatory
TDM samples were collected from 203 subjects on day 8
(n ¼ 201) or day 7 (n ¼ 2). In 1 subject conﬁrmatory TDM
was equivocal and not used. Consequently, 199 subjects had
2 sets of assessable PK parameters obtained with initial and
conﬁrmatory TDM.
Among the 199 subjects, median Bu clearance calculated
from initial TDM was 2.98 mL/min/kg (range, 1.95 to 4.39).
Overall, 2.9% of subjects had an AUC > 1500 mM$min and
32.8% of subjects had an AUC < 1000 mM$min (Figure 1).
Table 1
Patient Demographics (N ¼ 203)
Characteristics Value
Age, yr, median (range) 51 (19-72)
Male, n (%) 139 (67)
Race, n (%)
White 177 (87)
African American 13 (6)
American Indian or Alaskan Native 2 (1)
Asian 7 (3)
Other 4 (2)
ECOG performance status, n (%)
0 85 (42)
1 109 (54)
2 7 (3)
Missing 2 (1)
Body weight, kg, median (range) 83.4 (38.8-178.2)
Body mass index, kg/m2, mean (SD) 29.2 (6.3)
Classiﬁcations, n (%)
HL 66 (32)
NHL 137 (68)
DLBCL 74 (54)
FL 25 (18)
MCL 32 (23)
Other 6 (4)
Status at transplantation in ITT group, n (%)
CR1 55 (27)
CR2 66 (32)
CR3 or higher 5 (2)
Primary induction failure/in relapse 6 (3)
PR 71 (35)
Without prior CR 46 (22)
With prior CR 20 (10)
ECOG indicates Eastern Cooperative Oncology Group; SD, standard devia-
tion; ITT, intent-to-treat population.
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AUC target range if weight-based dosing had been used
without TDM. A greater proportion of obese (body mass
index  30) or overweight (body mass index 25.0 to 29.9)
subjects were underexposed to Bu comparedwith thosewith
normal body mass indices (18.5 to 24.9) (Table 2). However,
stratiﬁcation by body mass index was not sufﬁcient to
identify any speciﬁc patient population that would not have
required TDM. After PK-directed dose adjustments based on
initial and conﬁrmatory PK (AUC ¼ 20,000 mM$min  20%,
Figure 2) 95.0% of subjects fell within the target range for
total AUC; 3.0% and 2.0% subjects required additional dose
reductions and increases for the last 2 days, respectively.
Mean absolute error for the test dose predicted AUCday-8Figure 1. Measured AUC from .8 mg/kg of i.v. Bu as a preconditioning test PK
on of the days, day 14 to day 11 (n ¼ 204). Dotted line represents  20%
range of the target AUC (1000-1500 mM$min).(conﬁrmatory PK) was 7.4% (95% CI, 6.5% to 8.3%). Evaluating
the accuracy of test PK-based dose adjustments based on the
margin of error from the desired daily target exposure, mean
absolute error was 7.5% (95% CI, 6.5% to 8.4%). No signiﬁcant
change in clearance was observed between test PK and
conﬁrmatory PK (P ¼ .220, paired t-test), indicating that intr-
patient variability in clearance was minimal. Median total i.v.
Bu administered was 14.5 mg/kg of actual body weight
(range, 8.8 to 20.1). Bu exposure was similar to the overall
population in the subgroup of patients experiencing the AEs
of TRM or mucositis (Figure 3).
Adverse Events
An early subset analysis by age in June 2011 revealed that
4 of 17 subjects age > 65 years suffered TRM by day 100,
which met a protocol-speciﬁed stopping rule for this popu-
lation. The TRM rates by day 100 for all patients (n ¼ 203),
patients > 65 years (n ¼ 17), and patients  65 years
(n¼ 186) were 4.5% (95% CI, 2.1% to 8.3%), 23.5% (95% CI, 6.8%
to 49.9%), and 2.7% (95% CI, 0.9% to 6.2%), respectively. The
most common AEs leading to death were respiratory failure
(4 subjects, 1.9%), sepsis (3 subjects, 1.4%), multiorgan failure
(2 subjects, 1.0%), and acute respiratory distress syndrome
(2 subjects, 1.0%). Serious AEs with an incidence of 2% or
greater were recorded for 90 subjects (43.5%). The most
common grades 3 to 4 AEs observed in subjects  65 years
were febrile neutropenia (grade 3, 54%; grade 4, 3%), sto-
matitis (grade 3, 41%; grade 4, 0%), nausea (grade 3, 10%;
grade 4, 0%), and pneumonia (grade 3, 7%; grade 4, 0%). There
were no instances of seizure or hepatic veno-occlusive dis-
ease based on the Baltimore criteria [44]. Other grade3 AEs
are listed in Table 3.
Efﬁcacy of BuCyE
Efﬁcacy was analyzed for 186 subjects 65 years old with
HL (n ¼ 65) or NHL (n ¼ 121), including DLBCL (n ¼ 63), MCL
(n ¼ 29), and FL (n ¼ 23). Of the 186 patients, 156 (84%)
underwent transplant in PR or CR2 or higher. The remainder
(n¼ 30) underwent ASCT in CR1/CRu1 (complete remission 1
with a persistent radiographic abnormality of unknown
signiﬁcance), including 19 patients with MCL. With a median
follow-up of 20 months, the estimated rates of 2-year PFS
were 33% for HL and 58%, 77%, and 43% for DLBCL, MCL, and
FL, respectively. The estimated rates of 2-year OS were 76%
for HL and 65%, 89%, and 89% for DLBCL, MCL, and FL,
respectively. The OS and PFS curves for the phase II study of
PK-directed BuCyE are shown in Figures 4 and 5, respectively.
Comparisons of BuCyE with Matched CIBMTR Patients
Of the 186 patients, 183 recipients of BuCyE with lym-
phoma in complete or partial response were matched at a
maximum ratio of 4:1 with 729 CIBMTR control subjects
based on age, performance status, disease status before
transplant, and lymphoma histology. Nomatches were found
for 3 patients. In total, 177 patients had 4 matched control
subjects, and 97% of BuCyE-treated subjects had an age dif-
ference from control subjects of  5 years. A comparison of
patients from the phase II trial of BuCyE and the matched
cohort of patients conditioned with BEAM from the CIBMTR
is shown in Table 4. Patients were well-matched for age,
performance status, histologic subtype, and response before
transplant, and the median follow-up was 22 months in both
cohorts.
Two-year cumulative incidences of TRM were 3.3% (95%
CI, 1.4% to 6.6%) and 3.9% (95% CI, 2.4% to 5.7%) for BuCyE and
Table 2
AUC Exposure from Test Dose (.8 mg/kg i.v. Bu) by Body Mass Index Category
BMI Category (kg/m2) BMI (kg/m2)
(mean  SD)
Clearance (mL/min/kg)
Median (range)
AUC (n) Total (n)
<1000 mM$min <1000 to 1500 mM$min >1000 mM$min
Underweight (<18.5) 17.9  .51 2.76 (2.50-2.30) 0 4 (100%) 0 4
Normal (18.5-24.5) 22.9  1.63 2.85 (1.95-4.39) 10 (18.5%) 40 (74.0%) 4 (7.4%) 54
Overweight (25.0-29.9) 27.6  1.48 2.92 (2.15-4.11) 23 (33.8%) 42 (62.7%) 2 (3.0) 67
Obese (30.0) 35.4  5.10 3.16 (2.43-4.20) 34 (43.0) 45 (56.9%) 0 79
BMI indicates body mass index.
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were 76% (95% CI, 68% to 82%) and 78% (95% CI, 74% to 82%).
Tables 5 and 6 compare outcomes for NHL and HL separately.
Multivariate analysis demonstrated a signiﬁcant interaction
between disease and conditioning regimen in evaluation of
disease progression and treatment failure. Analyses by his-
tology demonstrated that among patients with NHL, there
were no differences in outcomes between groups. Among
patients with HL treated with BuCyE or BEAM, respectively,
the 2-year cumulative incidences of progression were 66%
(95% CI, 53% to 77%) and 38% (95% CI, 31% to 45%) and 2-year
PFS rates were 33% (95% CI, 21% to 46%) and 59% (95% CI, 52%
to 66%), with no difference in TRM or OS. The 2-year cumu-
lative incidences of TRM were 3.3% (95% CI, 1.4% to 6.6%) and
3.9% (95% CI, 2.4% to 5.7%) for BuCyE and BEAM, respectively.
Survival curves comparing BuCyE and BEAM conditioning
from this matched analysis for NHL and HL are shown in
Figures 6 and 7.DISCUSSION
This was the ﬁrst large-scale, multicenter, prospective
study in North America in which the i.v. weight-based Bu
dose was further adjusted based on PK results from a
preconditioning test dose. We found that simple pre-
conditioning TDM accurately estimated Bu clearance,
allowing for adequate conditioning dosing. Accuracy of the
test dose prediction and accuracy of test doseebased dose
adjustments were high, comparable with previous studies in
which clearance remained consistent across a pre-
conditioning test PK and a conditioning regimen for oral and
i.v. Bu [45-47]. Although infusion rates differed between
the test dose and the ﬁrst therapeutic dose by approximately
2- to 4-fold, infusion rateedependent nonlinear behaviorFigure 2. Histograms of estimated total AUC from test PK and conﬁrmatory PK
results (n ¼ 199). Dotted line represents the  20% range of the target AUC
(16,000-24,000 mM$min).was not noted. This may be due to determination of
Bu AUC and its estimated corresponding clearance using a
1-compartment model versus noncompartmental analysis.
Bu AUC estimates appear to more variable using non-
compartmental analysis [40]. In addition, a population PK
analysis demonstrated that Bu PK can be adequately
described by a linear PK model without interoccasional
variability [48]. In this study more than one-third of patients
would have had suboptimal exposure to i.v. Bu if weight-
based dosing alone had been used for conditioning,
whereas 95% of subjects achieved the target range of Bu
exposure after the introduction of individualized TDM.
A preconditioning test dose may be more convenient for
transplant centers relying on external PK laboratories and
can offer another opportunity for TDM on the ﬁrst day of
conditioning if the initial PK results are not assessable.
Results from the present study further showed that such
PK-directed Bu doses in combination with cyclophospha-
mide and etoposide constituted a tolerable regimen for
lymphoma patients < 65 years of age and was associated
with expected transplant conditioning toxicities and a TRM
< 5%. BuCyE was not well tolerated in patients  65 years,
resulting in unacceptable early TRM for older patients with
lymphoma. For patients with NHL, PK-directed i.v. BuCyE
produced similar PFS and OS to contemporary patients
treated with BEAM; however, a statistically signiﬁcant dif-
ference in PFS was observed between BuCyE and BEAM in
subjects with HL, indicating superior outcomes for BEAM in
terms of relapse and PFS. Although this trial and the addi-
tional matched cohort study design were not originally
powered to test the difference between the BuCyE and BEAMFigure 3. Scatter plot of total estimated Bu AUC for all patients and of actual
Bu AUC for patients with AEs of TRM and mucositis/stomatitis (M/S). Scatter
plots represent subjects with no M/S and grades (GR) 1, 2, and 3 M/S. There
were no cases of GR 4 M/S.
Table 3
Grades 3 to 4 AEs after PK-Directed BuCyE Conditioning (N ¼ 203)
Adverse event Grade 3 Grade 4 Total of
Grade  3
Febrile neutropenia 110 (54) 7 (3) 117 (57)
Stomatitis 84 (41) 0 84 (41)
Nausea 21 (10) 0 21 (10)
Hypophosphatemia 14 (7) 2 (1) 16 (8)
Pharyngeal inﬂammation
(esophagitis)
10 (5) 0 10 (5)
Pneumonia 15 (7) 0 15 (7)
Hypokalemia 12 (6) 1 (0.5) 13 (6)
Diarrhea 12 (6) 0 12 (6)
Decreased appetite 13 (6) 0 13 (6)
Hypoxia 11 (5.3) 1 (0.5) 12 (6)
Hepatic veno-occlusive disease
(Baltimore criteria)
0 0 0
Values are total number of cases with percents in parentheses.
Figure 5. PFS for the phase II study of PK-directed BuCyE conditioning and
ASCT for lymphoma. (A) HL/NHL. (B) NHL subtypes.
C.R. Flowers et al. / Biol Blood Marrow Transplant 22 (2016) 1197e12051202arms for subjects with HL, the sample size for the phase II
cohort subset and the 4:1 matching approach were reason-
ably large for examining this comparison and strength of the
association warrants notice.
Previous clinical data using Bu and cyclophosphamide
with or without etoposide have yielded clinical results that
are comparable with the other preparative regimens for
ASCT in both NHL and HL [4,7,24,26,27,29,30]. Bu exposure
(as assessed by AUC) has been associated with differences in
survival and AEs. Kebriaei et al. [49] showed that an opti-
mally dosed group had a signiﬁcantly better survival rate
than those with lower or higher exposures. Fixed-dose i.v. Bu
administration resulted in two-thirds of all subjects
achieving AUC values within the optimal window, but
PK-directed dosing increased the frequency of patientsFigure 4. OS for the phase II study of PK-directed BuCyE conditioning and
ASCT for lymphoma. (A) HL/NHL. (B) NHL subtypes.within the targeted range of AUC exposure up to 95%. The
2-year OS and PFS rates were 85% and 57%, respectively, for
patients with HL and 67% and 64%, respectively, for patientsTable 4
Characteristics of Patients Aged 65 Years in the Matched Analysis of Phase
II BuCyE and Contemporary Lymphoma Patients Treated with BEAM from
CIBMTR
BuCyE (n ¼ 183) BEAM (n ¼ 729)
Age at transplant, yr, median
(range)
52 (19-65) 50 (19-65)
Age group at transplant, n (%)
18-20 yr 1 (<1) 10 (1)
20-30 yr 23 (11) 102 (13)
30-40 yr 29 (16) 99 (14)
40-50 yr 38 (21) 153 (21)
50-60 yr 59 (32) 229 (32)
60-65 yr 33 (18) 132 (18)
Karnofsky score, n (%)
<90% 42 (23) 167 (23)
90% 139 (76) 552 (76)
Missing 2 (1) 6 (1)
Histology, n (%)
NHL
FL 23 (13) 90 (12)
DLBCL 62 (34) 246 (34)
MCL 29 (16) 112 (15)
Other 5 (2) 21 (3)
HL
Lymphocyte predominant 2 (1) 1 (<1)
Nodular sclerosis 46 (24) 212 (29)
Mixed cellularity 7 (4) 13 (2)
Lymphocyte depleted 0 2 (<1)
Nodular lymphocyte
predominant
2 (1) 11 (1)
Unclassiﬁed not further
speciﬁed
7 (4) 17 (2)
Table 5
Comparison of Outcomes for NHL Patients in the Matched Analysis of Phase
II BuCyE and Contemporary Lymphoma Patients Treated with BEAM from
CIBMTR
BuCyE (Estimate
n [95% CI])
BEAM (Estimate
n [95% CI])
P
TRM
No. of subjects 119 466
At 1 yr 4 (1-9) 3 (2-5) .626
At 2 yr 4 (1-9) 4 (2-7) .924
Relapse/progression
No. of subjects 119 466
At 1 yr 26 (19-35) 27 (23-32) .847
At 2 yr 36 (27-46) 41 (35-46) .410
PFS
No. of subjects 119 466
At 1 yr 69 (61-77) 70 (65-74) .984
At 2 yr 60 (50-69) 55 (49-60) .398
OS
No. of subjects 119 468
At 1 yr 83 (76-89) 84 (80-87) .839
At 2 yr 76 (67-84) 75 (70-79) .816
Figure 6. Comparison of survival for NHL patients in the matched analysis of
phase II BuCyE and contemporary lymphoma patients treated with BEAM from
CIBMTR. (A) OS. (B) PFS.
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NHL appear to be similar to BEAM in the present matched
analysis, this is not the case for HL.
One common concern of Bu-based conditioning for pa-
tients with HL has been the possibility of overlapping toxicity
with prior HL therapies such as bleomycin, alkylating agents,
and radiation. However, our ﬁndings do not suggest poor
outcomes from BuCyE due to excess toxicity or TRM. Indeed,
day 28 and day 100 TRM rates were 0% and 1.6%,
respectively, for HL patients who received BuCyE condi-
tioning. The primary differences observed between BuCyE
and BEAM in this analysis of HL patients was an increase in
early relapses, suggesting that BuCyE may be an inferior
regimen for disease control among patients with relapsed
HL.Why this regimenwould produceworse PFS in HL but not
in NHL or any NHL subtype remains unclear. A prior single-
institution study of 72 patients with HL or NHL conditioned
with either cyclophosphamide, etoposide, and carmustine or
BEAM found a higher prevalence of diarrhea in the BEAM
group (81% versus 51%, P¼ .0026) but a higher OSwith BEAM
than with cyclophosphamide, etoposide, and carmustine
(84% versus 60%); however, outcomes were not stratiﬁed byTable 6
Comparison of Outcomes for HL Patients in the Matched Analysis of Phase II
BuCyE and Contemporary Lymphoma Patients Treated with BEAM from
CIBMTR
BuCyE (Estimate
n [95% CI])
BEAM (Estimate
n [95% CI])
P
TRM
No. of subjects 64 253
At 1 yr 2 (0-6) 2 (1-4) .805
At 2 yr 2 (0-6) 3 (1-6) .514
Relapse/progression
No. of subjects 64 253
At 1 yr 55 (43-67) 30 (24-36) <.001
At 2 yr 66 (53-77) 38 (31-45) <.001
PFS
No. of subjects 64 253
At 1 yr 43 (31-55) 68 (62-74) <.001
At 2 yr 33 (21-46) 59 (52-66) <.001
OS
No. of subjects 64 255
At 1 yr 90 (82-96) 95 (92-98) .241
At 2 yr 76 (64-87) 85 (79-91) .168lymphoma subtype [50]. Chen et al. [51] compared outcomes
after ASCTacross different conditioning regimens and among
patients with HL and found that Bu-based regimens were
also associated with inferior outcomes.Figure 7. Comparison of survival for HL patients in the matched analysis of
phase II BuCyE and contemporary lymphoma patients treated with BEAM from
CIBMTR. (A) OS. (B) PFS.
C.R. Flowers et al. / Biol Blood Marrow Transplant 22 (2016) 1197e12051204Interpretation of our ﬁndings should also consider the
limitations of a nonrandomized comparison between the
patients and control subjects. Despite constructing a
matched cohort of CIBMTR patients for comparison,
unmeasured but important factors could be unbalanced be-
tween the 2 groups, which could bias the interventions.
Nevertheless, the matching strategy effectively identiﬁed a
large, contemporary cohort of patients who were similar in
age, performance status, and lymphoma subtype, which
were previously identiﬁed as important determinants of
outcome. Additionally, the control cohort patients were from
centers not participating in the clinical trial, which mini-
mized selection bias.
At present, identifying the preferred therapy for relapsed
HL remains complex, and themost effective form of HDTmay
differ by patient characteristics. Nevertheless, given the
dearth of randomized controlled trials to inform the man-
agement of patients with relapsed HL undergoing ASCT,
careful consideration of these ﬁndings should be undertaken
and BEAM conditioning should be preferred for patients with
HL undergoing ASCT when all other factors are equivalent.
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